FDA Cites K.C. Pharmaceuticals, Inc. in 2026-08-12 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
Here's the summary: On August 12, 2026, FDA's Center for Drug Evaluation and Research (CDER) issued Warning Letter 320-26-112 to K.C. Pharmaceuticals, Inc. (FEI 2026940, Pomona, CA) following a January 20–February 13, 2026 inspection, citing significant Current Good Manufacturing Practice (CGMP) violations for finished pharmaceuticals under 21 CFR parts 210 and 211. The violations include: failure to establish adequate written procedures for sterile aseptic processing with validated sterilization processes; continued manufacturing and release of sterile products after media fill failures on June 21, 2024, September 4, 2024, and November 4, 2024 without adequate root cause investigations; poor aseptic practices in ISO 5 areas (operators breaching barriers, improper technique); and inadequate airflow visualization studies with design deficiencies posing hazards to product sterility—a issue previously cited in an August 3, 2023 warning letter. The firm's responses were found inadequate for not conducting retrospective media fill reviews, not ensuring future operator compliance through oversight mechanisms, not investigating impact of poor practices on distributed products, and not addressing how previously distributed products would be evaluated for sterility assurance.
Argus analysis
# FDA Warning Letter Analysis: K.C. Pharmaceuticals, Inc.
**Company and Findings**
K.C. Pharmaceuticals, Inc., located in Pomona, California, received a Warning Letter from the FDA's Center for Drug Evaluation and Research (CDER) on August 12, 2026, following an inspection conducted January 20–February 13, 2026. The FDA identified significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. The agency determined that K.C. Pharmaceuticals' over-the-counter drug products are adulterated because the firm's manufacturing methods, facilities, and controls do not conform to CGMP standards.
**Regulatory Citations and Context**
The violations cited 21 CFR parts 210 and 211, which establish CGMP requirements for drug manufacturers. The specific deficiencies centered on 21 CFR 211.113(b), requiring written procedures to prevent microbiological contamination of sterile drugs and validation of aseptic and sterilization processes. The core issues included failed media fill validation tests (June, September, and November 2024), inadequate root cause investigations, poor aseptic practices in ISO Class 5 environments, and deficient airflow visualization studies. These violations represent fundamental gaps in sterility assurance for injectable and sterile products.
**Timeline and Industry Monitoring Points**
The firm submitted a response to the FDA 483 form on March 10, 2026, which the agency found inadequate. K.C. Pharmaceuticals committed to recalling affected batches and engaging external consultants but failed to address retrospective product evaluation and design remediation comprehensively. Compliance officers in pharmaceutical manufacturing should monitor whether K.C. Pharmaceuticals provides the detailed action plan the FDA demanded, including independent risk assessments, airflow studies under dynamic conditions, and comprehensive facility redesign timelines. A prior Warning Letter issued August 3, 2023, concerning smoke studies suggests a pattern of unresolved deficiencies warranting close observation.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER K.C. Pharmaceuticals, Inc. MARCS-CMS 729870 — August 12, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA EMAIL WITH READ RECEIPT Reference #: 320-26-112 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Ms. Ratnawati Li Recipient Title Chief Executive Officer K.C. Pharmaceuticals, Inc. 3420 Pomona Blvd. Pomona , CA 91768 United States Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-112 August 12, 2026 Dear Ms. Li: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, K.C. Pharmaceuticals, Inc., FEI 2026940, at 3420 Pomona Blvd., Pomona, CA, from January 20 to February 13, 2026. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your March 10, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. During our inspection, our investigators observed specific violations including, but not limited to, the following. 1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)). Media Fills Your firm continued to manufacture and release sterile drug products manufactured by aseptic processing following media fill failures on June 21, 2024, September 4, 2024, and November 4, 2024 as well as inconclusive media fill results and other significant quality events. Your firm lacked timely and adequate media fill investigations. For instance, your root causes were unsupported and lacked effective corrective actions. Following the inspection, you committed to recalling (b)(4) batches of drug products made from (b)(4) which reflects the timeframe between the failing media fills. In addition, you commit to improving your quality unit (QU) escalation procedures to ensure proper awareness and to engaging an outside consultant to provide oversight of your QU for six months. Your response is inadequate. You did not provide a retrospective review of all media fills to ensure additional deviations, atypical events, and unexpected results during commercial manufacturing were adequately represented in your media fill programs. Poor Practices in the Aseptic Processing Areas We observed poor practices and behaviors in ISO 5 areas during commercial operations and media fills. These poor …
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- When did FDA issue the warning letter to K.C. Pharmaceuticals, Inc.?
- FDA issued the letter (MARCS-CMS 729870) on 2026-08-12 and posted it publicly on fda.gov on 2026-08-18.
- Is the FDA warning letter to K.C. Pharmaceuticals, Inc. publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kc-pharmaceuticals-inc-729870-08122026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites K.C. Pharmaceuticals, Inc. in 2026-08-12 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-k-c-pharmaceuticals-inc-2026-08-12-cgmp
"FDA Cites K.C. Pharmaceuticals, Inc. in 2026-08-12 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-k-c-pharmaceuticals-inc-2026-08-12-cgmp.
Argus HQ Research. "FDA Cites K.C. Pharmaceuticals, Inc. in 2026-08-12 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed August 19, 2026. https://argushq.ai/fda/warning-letter/fda-wl-k-c-pharmaceuticals-inc-2026-08-12-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_k_c_pharmaceuticals_inc_2026_08_12_cgmp_2026,
title = {FDA Cites K.C. Pharmaceuticals, Inc. in 2026-08-12 Warning Letter — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-k-c-pharmaceuticals-inc-2026-08-12-cgmp},
note = {Accessed: August 19, 2026}
}